Skip to main content
. 2006 Sep;55(9):1350–1359. doi: 10.1136/gut.2005.076646

graphic file with name gt76646.f1.jpg

Figure 1 Development of therapy for chronic hepatitis C is a story of success. Sustained virological response rates have been improved from approximately 5% with interferon (IFN) monotherapy in the early 1990s to >60% with the optimised standard therapy of pegylated IFN (PEG‐IFN) and ribavirin.